The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isThe human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
- What to watchPain under the right ribs after meals.
How Livagen works
Lys-Glu-Asp-Ala — a defined tetrapeptide targeting hepatic tissue.
- Injectable
On the goal map: Hepatocyte protection & liver function (Detox & liver support)
Research on Livagen5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
Correlative data
Used for liver support. The most interesting published item on it is not a liver finding — Khavinson's group reported chromatin decondensation in lymphocytes from elderly donors, which is one of the few cell-level results in the series that others could in principle repeat.
How the mechanism reads
Lys-Glu-Asp-Ala — a defined tetrapeptide targeting hepatic tissue.
MechanisticThe shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
MechanisticThe chromatin work is where this hypothesis is most testable. Decondensation is measurable, and a replication attempt by any independent cytogenetics lab would settle a great deal about the whole series. That it has not happened in twenty years is itself informative.
Mechanistic
Sources
- Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu. Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People. Bulletin of Experimental Biology and Medicine 2002;134(4):389–392 · PMID 12533768
- Riadnova IIu, Filippov SV, Iuzhakov VV. Functional morphology of an organotypic liver culture exposed to the peptide livagen. Advances in Gerontology 2002 [Russian] · PMID 12577697
- Brodskii VIa, Khavinson VKh, Zolotarev IuA, Nechaeva NV, Malinin VV, Novikova TE, Gvazava IG, Fateeva VI. Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izvestiia Akademii Nauk Seriia Biologicheskaia 2001 [Russian] · PMID 15926314
- Timofeeva NM, Khavinson VKh, Malinin VV, Nikitina AA, Egorova VV. Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Advances in Gerontology 2005 [Russian] · PMID 16075683
- Kost NV, Sokolov OIu, Gabaeva MV, Zolotarev IuA, Malinin VV, Khavinson VKh. Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii Nauk Seriia Biologicheskaia 2003 [Russian] · PMID 12942748
- Dzhokhadze TA, Buadze TZh, Dvalishvili NA, Lezhava TA. Variability of radiation-induced adaptive response in old age individuals and their correction by peptide bioregulator Livagen. Georgian Medical News 2007 · PMID 17921545
- Lezhava T, Jokhadze T. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences 2007 · PMID 17460203
- Lezhava T. Epigenetic modification under the influence of peptide bioregulators on the old chromatin. Georgian Medical News 2023 · PMID 37042594
Livagen safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Undiagnosed liver or gallbladder symptoms such as right-sided pain or yellow eyes.
- Active cancer, as chromatin activation changes cell behavior in lymphocytes.
- Hepatitis or autoimmune liver disease.
- Pregnancy or breastfeeding, as chromatin-modifying peptides have no reproductive data.
What’s expected
- Nothing immediate; the claim is hepatocyte and lymphocyte chromatin changes.
- Digestive enzyme activity shifts have been reported in Russian work.
- Mild nausea in some.
Watch for
- Pain under the right ribs after meals.
- Itching with pale stool or dark urine.
- New fatigue with loss of appetite.
Labs that tell you it’s working
- Comprehensive Metabolic Panel: ALT, AST and bilirubin show the liver the peptide targets.
- Lipase: digestive enzyme activity was part of the reported effect.
- hs-CRP: a lasting rise would argue against the claimed benefit.
Liver and gut bioregulator tetrapeptide studied for chromatin activation in lymphocytes and digestive enzyme activity; human data are Russian and small. PMID 12533768 PMID 16075683
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Livagen FAQ4 common questions
- Is Livagen approved for human use?
- No. Livagen is a research compound.
- What is Livagen researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- Comprehensive Metabolic Panel; Lipase; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Livagen: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



